Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2011-08-22 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
New National Stockist for ELIXIA Personal Care Product Range 2 pages 81.2KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 23 August 2011, describing a new national stockist agreement for the Elixia® personal care product range by Phosphagenics Limited. It discusses retail partnerships, product details, and distribution plans. There is no financial data, regulatory filing references, or report attachments. The content is promotional and informative about business developments rather than financial results or governance. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general company announcement about business activity, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2011-08-22 English
PGL: Progen Subsidiary Secures New Manufacturing Contracts 2 pages 93.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing new manufacturing contracts secured by a subsidiary of Progen Pharmaceuticals Ltd. It discusses business developments and contract details but does not contain financial statements, regulatory filings, or detailed financial performance data. There is no indication that this is an earnings release, annual report, or any other formal financial or regulatory filing. The content is primarily a corporate announcement about business activities and partnerships. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories, which corresponds to Regulatory Filings (RNS). The document length is under 5,000 characters, and it is not announcing the publication of a report but rather a business update, so it is not a Report Publication Announcement (RPA).
2011-07-19 English
Major Distribution Agreement for Asia for ELIXIA Products 2 pages 48.9KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about Phosphagenics signing a major distribution agreement for its Elixia personal care range in Asia. It discusses the deal details, product launch plans, and company strategy but does not contain any financial statements, regulatory filings, or detailed financial data. The document length is 3839 characters, which is relatively short and reads like a press release or announcement rather than a formal report. There is no indication that this is an Annual Report, Earnings Release, or any other formal financial or regulatory filing. It is clearly an announcement of a business development (distribution agreement). Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and company news that do not fit other specific categories.
2011-07-05 English
Change of Director`s Interest Notice Appendix 3Y 3 pages 26.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including the number of securities held before and after the change, nature of the change, and dates. It includes specific information about the director's securities transactions and interests. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a financial report itself, but a regulatory disclosure of insider trading activity.
2011-07-03 English
Elixia range of Personal Care Products - Update 2 pages 48.6KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 28 June 2011 from Phosphagenics Limited. It discusses sales progress, new stockists, product details, and strategic plans for market expansion. There are no financial statements, regulatory filings, or detailed financial performance data. The content is promotional and informative about sales milestones and business development rather than a formal financial report or regulatory filing. The document length is 3886 characters, which is relatively short and reads like a press release or business update. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS) as a general company announcement that does not fit other specific categories.
2011-06-27 English
Reconciliation of Unquoted Options 8 pages 112.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 3B New Issue Announcement filed with ASX, detailing the issue and expiry of unquoted employee stock options (ESOP) by Phosphagenics Limited. It includes specifics such as issue price, exercise price, expiry date, and reconciliation of securities. The document is a formal announcement of new securities issued and changes in capital structure, not a full financial report or earnings release. It is regulatory in nature, focused on capital changes and securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement but a detailed regulatory filing about new securities issuance.
2011-06-05 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.